论文部分内容阅读
目的观察肿瘤干细胞标记物泛素特异性肽酶22(USP22)蛋白在神经母细胞瘤中的表达,探讨其在神经母细胞瘤发生发展过程中的作用。方法用免疫组化法检测USP22蛋白在68例神经母细胞瘤组织和瘤旁组织细胞中的表达,结合临床资料分析其与临床病理学特征的关系。结果免疫组织化学染色结果显示USP22主要在肿瘤细胞核中呈阳性表达,而瘤旁组织中呈阴性表达。进一步统计分析,USP22在Ⅲ~Ⅳ期肿瘤中的表达水平高于Ⅰ~Ⅱ肿瘤(P<0.05);USP22在有淋巴结转移组的表达水平明显高于无淋巴结转移组(P<0.05);而USP22在神经母细胞瘤中的表达水平与性别、年龄、大小、肿瘤部位、病理分型等参数无相关性(P>0.05)。结论 USP22在神经母细胞瘤细胞中有表达,其表达水平与肿瘤的临床分期及是否淋巴结转移有相关性,与性别、年龄等参数无明显相关性。
Objective To observe the expression of the tumor stem cell marker ubiquitin-specific peptidase 22 (USP22) protein in neuroblastoma and to explore its role in the development of neuroblastoma. Methods The expression of USP22 protein was detected by immunohistochemistry in 68 cases of neuroblastoma and para-tumorous tissues. The clinical data was used to analyze the relationship between the expression of the USP22 protein and clinicopathological features. Results The results of immunohistochemistry showed that USP22 was mainly expressed in the nucleus of tumor cells and negatively in the tumor-adjacent tissues. Further statistical analysis showed that the expression level of USP22 in stage Ⅲ-Ⅳ tumors was higher than that in stage Ⅰ-Ⅱ tumors (P <0.05). The expression level of USP22 was significantly higher in patients with lymph node metastasis than in those without lymph node metastasis (P <0.05) The expression level of USP22 in neuroblastoma had no correlation with gender, age, size, tumor location, pathological type and other parameters (P> 0.05). Conclusions USP22 is expressed in neuroblastoma cells. The expression level of USP22 is correlated with clinical stage and lymph node metastasis, but not with sex, age and other parameters.